Global Safety Board

MMV’s Global Safety Board (GSB) was instituted in 2009 and is mandated to conduct a review on projects that are progressing to testing for the first time in humans. The board continues to conduct a thorough scientific and ethical review at each major project milestone beyond the clinical phase 1 of the R&D process, through to registration and distribution

Global Safety Board Members

Dr Trevor Gibbs Senior Vice President, Pharmacovigilance & Medical Governance, GlaxoSmithKline, UK; and Co-Chairman of MMV Global Safety Board, UK

Dr Stephan Duparc Chief Medical Officer, MMV, Switzerland; and Co-Chairman of MMV Global Safety Board, Switzerland

Sir Colin Dollery Senior Consultant, Glaxo-SmithKline Research and Development, UK

Prof. Tim Hammond Preclinical Safety Consulting Ltd, UK

Dr David McGibney Pharmaceutical research and development expert; Consultant Pharmaceutical Physician, UK

Dr John Pears Director, Woodhouse Green, UK